Product Information

CLINDA-TRETINOIN 1.2%-0.025% is a generic product labeled by Solaris Pharma Corporation, priced at $4.3282 per GM under NDC 73473030630. Its NADAC has been published 219 times since Jun 15, 2022.

FDA first approved this application on Feb 10, 2022. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

CLINDA-TRETINOIN 1.2%-0.025%

clindamycin phosphate and tretinoin
$4.3282per GM

Strength

10; .25 mg/g; mg/g

NDC

73473030630

Classification

Generic

Dosage Form

GEL

Route

TOPICAL

Effective Date

8/19/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA212845

FDA Approved

2/10/2022

TE Code

AB2

On Market Since

1/3/2025

Pharmacological Classes

Decreased Sebaceous Gland Activity
Lincosamide Antibacterial
Lincosamides
Neuromuscular Blockade
Retinoid
Retinoids

Price Statistics

The NADAC for CLINDA-TRETINOIN 1.2%-0.025% has been published 219 times since Jun 15, 2022, and over the history we have for it it has declined 27.4%. The table below summarizes its recorded NADAC range and movement.

Current price$4.3282 per GM
All-time high$7.5670 (Oct 11, 2023)
All-time low$4.3282 (Aug 19, 2026)
52-week high$4.9717
52-week low$4.3282
Median price$5.5383
Average price$5.6688
Largest weekly change-31.8% (Dec 20, 2023)
Weeks tracked219
Tracking sinceJun 15, 2022

Price History

1W

-6.0%

1M

-6.0%

3M

-12.9%

6M

-5.4%

1Y

-4.5%

3Y

-42.8%

5Y

N/A

All

-27.4%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 22% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 22%

1 alternative • Same active ingredient

Frequently asked questions

What is the NADAC price of CLINDA-TRETINOIN 1.2%-0.025%?

The current National Average Drug Acquisition Cost (NADAC) for CLINDA-TRETINOIN 1.2%-0.025%, manufactured by Solaris Pharma Corporation, is $4.3282 per GM (NDC 73473030630), effective Aug 19, 2026.

How has the price of CLINDA-TRETINOIN 1.2%-0.025% changed over time?

Over the history we have for it, the NADAC for CLINDA-TRETINOIN 1.2%-0.025% has declined 27.4%. It has been tracked across 219 weekly CMS publications since Jun 15, 2022.

What are the highest and lowest recorded NADAC prices for CLINDA-TRETINOIN 1.2%-0.025%?

Since Jun 15, 2022, the NADAC for CLINDA-TRETINOIN 1.2%-0.025% has ranged from a low of $4.3282 (Aug 19, 2026) to a high of $7.5670 (Oct 11, 2023), with a median of $5.5383 per GM.

Are there cheaper alternatives to CLINDA-TRETINOIN 1.2%-0.025%?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CLINDA-TRETINOIN 1.2%-0.025%, is $3.3975 per GM — about 22% below CLINDA-TRETINOIN 1.2%-0.025%.

Who manufactures CLINDA-TRETINOIN 1.2%-0.025%?

CLINDA-TRETINOIN 1.2%-0.025% (NDC 73473030630) is labeled by Solaris Pharma Corporation, and CMS classifies it as a generic product.